Malignant Cervical Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant neoplasm involving the cervix. 
Malignant cervical neoplasms most frequently harbor alterations in PIK3CA, TP53, KRAS, KMT2D, and ERBB2 .
PIK3CA Mutation, PIK3CA Codon 545 Missense, PIK3CA E545K, TP53 Mutation, and TP53 Missense are the most common alterations in malignant cervical neoplasm .
There is 1 clinical trial for malignant cervical neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant cervical neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
TREM1 is the most frequent gene inclusion criterion for malignant cervical neoplasm clinical trials .
Py159 and pembrolizumab are the most common interventions in malignant cervical neoplasm clinical trials.
Significant Genes in Malignant Cervical Neoplasm
ERBB2 is altered in 9.5% of malignant cervical neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant cervical neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant cervical neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.